In 2016, a study showed that the fluorescent-labeled anti-CEACAM6 probe (CEACAM6-Alexa Fluor488) can label the tumors in patient-derived tumor xenografts (PDTX) (13), however, its diagnostic value in preneoplastic lesion has not yet been investigated. This evidence concerns the gene CEACAM6 and neoplasm.